Loading
A phase 3 trial of AZD0486 in follicular lymphoma, run by AstraZeneca, now recruiting.
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients is a phase 3 interventional study registered as NCT06549595 by AstraZeneca, with 1018 participants planned, started 2024-08-07 and due to reach its primary completion in 2031-11-26. Interventions recorded: Surovatamig, R-CHOP, R-CVP, BR. Conditions listed: Untreated Follicular Lymphoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AZD0486, Follicular lymphoma, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Shares AZD0486, AstraZeneca.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/